v3.26.1
Net financial results (Tables)
3 Months Ended
Mar. 31, 2026
Notes and other explanatory information [abstract]  
Disclosure of finance income (cost) [text block]
03/31/202603/31/2025
Financial expenses
Interest on loans, financing and debentures (1)

(1,401,182)
(1,360,125)
Premium expenses on early settlements (2)
(129,047)
Amortization of transaction costs

(58,457)
(31,923)
Interest expenses on lease liabilities (3)

(113,211)
(116,258)
Other

(103,034)
(131,779)
(1,804,931)
(1,640,085)
Financial income

Cash and cash equivalents and marketable securities

464,425 
348,428 
Other
21,588 
90,425 
486,013 
438,853 
Results from derivative financial instruments

Income

3,477,696 
4,224,351 
Expenses
(452,097)
(531,192)
3,025,599 
3,693,159 
Monetary and exchange rate variations, net

Exchange rate variations on loans, financing and debentures

3,419,196 
5,702,984 
Leases
119,661 
199,040 
Other assets and liabilities (4)
(629,102)
(697,738)
2,909,755 
5,204,286 
Net financial result
4,616,436 
7,696,213 
(1)Excludes R$24,929 arising from capitalized loan costs, substantially related to property, plant and equipment in progress of the Cerrado Project for the three-month period ended March 31, 2026 (R$52,753 as at March 31, 2025).
(2)R$ 121,752 related to the costs of early termination of the pre‑approved and undrawn credit facility with Finnvera.
(3)Includes R$64,577 referring to the reclassification to the biological assets item for the composition of the formation cost (R$66,200 as of March 31, 2025).
(4)Includes effects of exchange rate variations of trade accounts receivable, trade accounts payable, cash and cash equivalents, marketable securities and others.